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Colorectal cancer is the second cause of cancer related death in developed countries. It 
is of major concern for public health authorities which are interested in large population 
screening for CRC, as early identification leads to decreased mortality. Unfortunately 
classical clinical diagnosis methods are too expensive to be applied for large screening. The 
development of rapid, low cost, easy and accurate tools for CRC diagnosis is needed. 
Biomarkers as sensitive than specific, able to achieve prognosis of CRC and correlated to 
clinical features still remain elusive. But the growing fields of new techniques like proteomic 
ones might be a suitable option to discover new specific biomarkers for CRC and for 
developing new tools of diagnosis. These techniques have already given new insights in 
various cancers and other diseases. This paper reviews the current knowledge in the fields of 
proteomics dedicated to CRC and more precisely to CRC diagnosis. 
 
Résumé  
Le cancer du colon est le deuxième cancer le plus mortel dans nos pays développés. 
Les autorités responsables de la santé publique souhaiteraient pouvoir effectuer des dépistages 
systématiques du cancer du colon, puisque un diagnostic précoce réduit les risques de 
mortalité. Malheureusement le coût des méthodes classiques de diagnostic est actuellement 
trop important pour envisager un dépistage systématique à grande échelle. Le développement 
de nouveaux outils diagnostiques, rapides,  faciles, peu coûteux et efficaces pour le cancer du 
colon est donc nécessaire. Néanmoins, des biomarqueurs aussi sensibles que spécifiques, 
capables de diagnostiquer les stades précoces de cette maladie et corrélés aux méthodes 
cliniques classiques de diagnostic reste un idéal non atteint. Des techniques émergeantes et 
puissantes de protéomique peuvent constituer une option séduisante et adaptée afin de 
découvrir de nouveaux biomarqueurs spécifiques du cancer du colon et permettre le 
développement de nouveaux outils diagnostiques. Le nouveau champ de recherche qu’est la 
protéomique clinique et les technologies qu’elle exploite ont déjà porté leurs fruits dans le cas 
d’autres cancers et autres pathologies. Le but de ce papier est de rassembler et commenter les 
découvertes  et progrès constants faits dans le domaine de la protéomique appliquée au cancer 




Despite the increasing knowledge on colorectal cancer etiology and the growing 
development of specific therapies and diagnosis tools, CRC is still the second cause of cancer 
related death in western countries. The early diagnosis of CRC or any preceding stages 
presenting colon abnormalities (including adenomatous polyps or plane lesions) is required to 
increase chances of survival [1]. Nowadays, CRC diagnosis still relies on classical clinical 
methods like colonoscopy, double contrast barium enema, or the recent Virtual Colonoscopy 
(or Computed Tomographic Colonography). This last one presents the advantages of being 
less invasive than endoscopic colonoscopy, necessitating less radiation than contrast barium 
enema and following some technical improvement might even be performed without any 
bowel preparation, tagging the stools with contrast agent. Nevertheless it sensitivity seems to 
be variable depending on case reports [2]. But, such techniques are to some extent risky 
(accidental perforations have been recognized both with endoscopic or virtual colonoscopy) 
and are too expensive to be used as large screening tools. Only a few molecular based 
diagnosis tests, performed in particular conditions, are recommended for CRC diagnosis and 
follow up: CEA (carcinoembryonic antigen) in blood or faeces, CA19-9 (gastrointestinal 
carbohydrate antigen 19-9), faecal occult blood test (FOBTs). As CRC early diagnosis is an 
important public health consideration, many governments (United States, Denmark, UK and 
Australia) are involved in studying, prospectively, on large cohorts of people the effect of the 
use of molecular diagnosis testing on CRC mortality. FOBTs, CEA and CA19-9 appear to be 
interesting in many CRC stages or are prognosis factors. CRC screening using FOBTs has 
been shown to decrease the CRC-related mortality in several large population studies [1]. 
However this technique is flawed by a significant proportion of false negative. CEA and 
CA19-19 have no demonstrated value as a screening or diagnostic tool. They are essentially 
usefull for purposes like monitoring recurrence after surgery and other treatments [3, 4]. But, 
their specificities and sensitivities taken solely are not satisfying. That is the reason why, 
beside these markers of tumours burden, numerous teams are assessing with classical 
strategies new molecules and their producing and downstream metabolic events, in order to 
implement the diagnosis of CRC [4]. 
 
Among these markers still under study, one might notice genetics factors like Ras 
family gene mutations, P53 mutations, microsatellite instability and chromosomal 
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translocations; molecules involved in angiogenesis, like VEGF, cell adhesion molecule; 
inflammatory related molecules, like Tissue Factor, S100A4, CRP and various components 
involved in many pathways, like nuclear matrix protein (NMP), Thymidylate synthase (TS) 
mRNA, some polyamins and the von Willebrand factor [4-9] . Unfortunately, these markers 
are not highly specific to CRC, as they are also found in other cancer types. Then, many 
authors propose to use several markers combined in multivariate model in order to obtain 
more specific and accurate diagnosis of CRC [10, 11]. 
 
In this context, the evolving techniques of proteomics are interesting to discover new 
biomarkers in various contexts. Clinical proteomics is an emerging area already reporting 
many advances in the field of diagnosis of various pathologies as cancer [12-14]. Hence, it 
allows the evaluation of particular proteomes through very sensitive technical approaches and 
arises with the possibility of monitoring and combining many biomarkers in one single test. 
Moreover, it shows high throughput screening capabilities. Among the vast ongoing 
publications reported to date, this paper will focus on proteomics contribution to the discovery 
of news potential specific CRC biomarkers and also on the development of new diagnosis 
tests for CRC, based on protein profiling. 
 
1. General considerations about proteomic techniques 
 
 Several technologies like 2D-gel electrophoresis or others specialized in proteins 
profiling exist and are dedicated to the study of the comparison of proteins expressed in 
particular conditions by a tissue or present in a given body fluid. These allow the 
determination through accurate statistical methods, of some proteins or peptides differentially 
found present in one or the other compared sample. Two rational strategies exist in the current 
works reported. Generally, scientists study biomarkers of interest individually in details, 
purifying and identifying them, correlating either their proteomic observations with classical 
methods. The second strategy uses all the data collected in the profiles and designs many 
models of classification with robust bioinformatics and statistical tools. The protein signature 
obtained may therefore orientate the classification of the sample in a given category, without 
knowing the identity of all protein factors contributing to the final diagnosis. Nevertheless, 
due to the difficulty of replication of such integrative diagnostic or predictive profiles, the 
scientific community stay very cautious with this second option and prefers to establish 
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models of classifications with identified biomarkers, which are consistent with the 
etiopathology. 
 Samples of different  origins can be compared ranging from model cell lines, body 
fluids (sera, plasma, urine, ascites, tears...) or cells derived from animal models and from 
patient tissues (biopsies, blood cells…). These samples are diluted or can even be fractionated 
in order to detect minor proteins. Moreover, by comparing patients subjected to various 
diseases managements, diets, over long periods of time, presenting different stages or grades 
of disease…, these proteomic techniques may provide valuable and complete data. 
Clinical proteomic advances made and new insights brought by these techniques are 
reviewed in [15]-[16]. Techniques as various as 2D gel electrophoresis, profiling on SELDI-
TOF-MS or MALDI-TOF-MS, MALDI imaging and combinations of several technologies 
like LC/MS-MS, 2DLC/MS-MS, ICAT, SILAC, nanotechnologies provides strong platforms 
with various capabilities. One advantage is in the power of mass spectrometry which have 
been developed and used primarily for assessing quality controls for example, in 
pharmaceutical industry. Mass spectrometry usually requires very small sample quantity. In 
addition to its sensitivity, it brings the information on mass very precisely, which is an 
element not available by classical techniques. This way giving access to possible 
posttranslational modifications or variant isotypes, differing in mass and which can be missed 
by other techniques like classical Western blotting or ELISA. Another strength of the overall 
strategy is the fractionation of samples. This preparation step is based on classical and well 
known methods of biochemistry and may be completely standardized and transposed to 
nanoscale, reducing time, variation and consumption of precious materials. Hence, proteomic 
evolving very rapidly towards more automation and reproducibility, it should soon satisfy 
robustness required in clinical diagnosis, predicting in the near future new developments in 
this area and new diagnosis solutions. The study by proteomic of pathologies as frequent as 
CRC is more and more popular judging by the numerous publications reported to date. 
 
2. Proteomic on CRC 
 
2.1. Serum profiling 
 
 The recently developed SELDI-TOF-MS technology is based on the binding of 
proteins on chemically activated groups coated on chip arrays. These on chip purified proteins 
are resolved with a Surface Laser Enhanced Desorption Ionisation Time Of Flight Mass 
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Spectrometer, which reconstitute profiles according to the panel of proteins detected [17, 18]. 
This technology has been used in several studies with serum of CRC patients with good 
success [19-22]. Authors use serum of patients suffering from CRC at different grade or stage 
(Dukes grades and stages I to VI). They prepared samples by running a pre fractionation 
directly on chip arrays and obtained different protein patterns as they utilised different nature 
of chips. They all used sophisticated bioinformatic machine learning algorithm and artificial 
neural networks classification tools to manage data profiles and propose models of 
classification based on a few selected potential biomarqueurs. These were able in these first 
studies to differentiate CRC from healthy patients and even differentiate grades or stages of 
CRC, with excellent sensitivity and specificity. Nevertheless, none of these teams have 
performed or yet published validation or blind test to confirm these results. More completed 
works have been performed with SELDI-TOF-MS on biopsies and were confirmed in sera 
[19]. Finally, another group interested in prostate cancer has reported a complete study, using 
SELDI-TOF-MS serum profiling and achieve accurate discrimination of patients. They 
validated successfully their models on several SELDI platforms, located in USA and Europe. 
They also advised modalities to control reproducibility with this technique, attesting of efforts 
made to answer general criticisms on SELDI-TOF-MS [20]. 
 
2.2. Patient’s biopsy 
 
Proteomic study of biopsy is probably the more documented one and is by far less 
criticised. Indeed, every patient may possibly be its own negative control, in the comparison 
of tumour tissue and not affected neighbouring one. But, the sensitive question relies more on 
the possibility to use lazer microdissected cells, separating tumour cells from contact 
epithelial cells or else the entire biopsy with every tissue types included [16]. 
Studies with the quite sensitive 2D-DIGE gel electrophoresis and identification of 
differentially expressed proteins by MALDI-TOF-MS have been recently reported [21], [22]. 
These works focus either on biopsies from tumour cells and adjacent non tumour tissue from 
CRC patients or on biopsies from patients suffering from CRC at different sites. They 
identified more than 32 proteins differentially present among groups, but only the last authors 
confirmed part of their results by specific immunoblotting or immunohistochemistry. Among 
other, they confirmed several variant isoforms and a phosphorylated form of vimentin, 
cytokeratin 8 and 19, calreticulin, apolipoprotein A1… This work revealed category and 
family of proteins found previously involved in carcinogenesis by classical genomics and in 
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other proteomic studies: MAT-1 (a protein identified from metastatic mammary 
adenocarcinoma cell line), cathepsin D and calreticulin [22]. However, such time consuming 
studies can only be run on a few samples at a time and the relevance of candidate biomarkers 
should be addressed in larger cohort of patients, to reach statistical significance. 
 In contrast to 2D-DIGE, SEDLI-TOF analysis can be performed on many sample 
lysates of tumour and non tumour tissue to obtain statistical significance. Many teams used 
this strategy with success allowing the discovery, in a rather small study, of a group of not yet 
identified peptides in the mass range of 3.4 to 3.6 kDa, which were increased in CRC tumour 
cells[23]. Moreover, two very elegant and complementary works have been performed by 
independent groups[24],[19]. They both reported in tumour cells and in sera, that CRC 
patients showed increased levels of α-defensin 1, 2, 3 peptides or HNP1-3, at mass 3372, 
3442 and 3486Da. These observations were confirmed through other techniques like 
immunohistochemistry which gave the repartition of HNP1-3 in tumour cells and in normal 
surrounding tissues, as macrophages and fibroblasts of the mucus membrane indicating some 
potential roles of these peptides in the aetiology of many cancers and in inflammatory 
pathologies like inflammatory bowel disease. Of course, similar strategies can be transposed 
to study drugs metabolism and further follow up and management of CRC patients, like 
proposed in the evaluation of cytochrome P450 by proteomic approach [25]. 
 Some authors reported the discovery of two proteins specifics for CRC development, 
using tumor microdessected cells from adenoma and normal colon cells. They identified 
HSP10 by proteomic profiling. This heat shock protein 10 was found increased in CRC 
adenoma and confirmed by direct immunolabelling of tissue sections and by Western blotting 
analysis on cell lysates [26]. They else reported the comparison of protein profiles generated 
on SELDI-TOF-MS with normal, adenoma and carcinoma microdissected cells of colon. 
Among proteins found differentially present, there was Calgizzarin (or S100A11), which 
could be further confirmed by specific immunodepletion from the original sample at expected 
peak position in spectra and by immunohistological analysis.  
 Recent developments of proteins microarray analysis have been realized, combining 
data from genomic and proteomic discovery. For example, in CRC diagnosis, Belluco and 
Lise tested the use of a specific phosphoprotein chip array. This includes the use of 29 
specific antibodies targeting phosphoproteins known to be part of end point signalling 
cascades involved in carcinogenesis, like clived Caspase 3, Erb2, ERK or NF-kB P65. They 
utilized neoplastic microdissected cells from primary CRC, with and without liver metastases 
and liver metastases cells, to characterise the answers, on chip of these non invasive or 
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invasive stages of CRC. They used sophisticated bioinformatics and mathematical tools to 
associate different metabolic phosphoproteomic profiles with CRC stages [27]. They assume 
that microenvironment involves different signalling pathways that can be sensed with this 
type of techniques. Thus, similar tools might be developed assessing the biomarkers or 
signature of patients utilising for example the well characterised biomarkers proposed in 
proteomic study. 
 
3. Emerging techniques and strategies 
 
 The field of proteomics combines technologies which are in constant evolution and 
improvement. For example, mass spectrometry instruments constructors which develop 
engines which are robust and efficient, automatized and easy to use. Some of these can be 
dedicated to various application like identification of protein, protein profiling, quantitative 
proteomics using methods like isotope coded affinity tag (ICAT), isotope tag for relative and 
absolute quantitation (iTRAQ™) or stable isotope labelling of amino acid in cell culture 
(SILAC) and application for imaging (MALDI imaging), which is also commercialised. 
Moreover, they may be combined with various scale purification platforms, microflow or 
nanoflow HPLC, enabling better separation of products for analysis of pure species. The nano 
technologies are of particular interest knowing recent developments in biomaterials designed 
for purification, a very important step for correct protein identification by sequencing. In 
addition, efforts have also been made to improve 2D gel based analysis with the 2D-DIGE 
technology, which uses more sensitive dyes than conventional silver staining or coomassie 
blue procedures. Indeed, different samples to be compared are stained with particular dyes 
and are resolved at the same time, on the same gel avoiding misinterpretation. Finally, 2D 
LC/MS-MS techniques arose combining directly the advantage of chemical derivatisation 
which label sample, and the separation of proteins unresolved by 2D gel, like very basic or 
acidic ones [16]. 
 But in the context of clinical diagnosis, protein profiling on chip or after purification 
steps with chemically activated microbeads, MALDI imaging and related techniques are 
probably the more exciting methods. Protein profiling would allow the determination of 
particular signatures of proteins and peptides, to be informative for different pathological 
states. These instruments and techniques, like SELDI-TOF-MS or MALDI-TOF-MS profiling 
are therefore moving towards an adaptation to diagnosis in medical area. MALDI imaging 
will probably be a complement to classical histological analysis. It is based on protein 
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profiling directly on tissue section. Then, it may directly target total protein content of an 
embedded tissue portion with very little step of preparation and no need of presolubilization 
or fractionation of sample. Nevertheless, tissue preparation for MALDI analysis has to be 
optimized in order to enhance desorption of constituting molecules. Moreover, MALDI 
Imaging should also provide spatial information on proteins, with localised concentration as 
computer program can build 3 dimensions views of a piece of tissue, with its serial slices [28].  
  
4. Perspectives and concluding remarques: 
 
Proteomics is certainly a very broad field and the integration of all works achieved in 
the area will open new perspectives in the diagnosis of malignancies. The data generated 
should be shared and organised in order to establish “proteomes analysis of human”, like it 
was realised for human genome sequencing. But, these information exchanges would need 
even more energy and organisation, as proteome is certainly broader then genome. Indeed, 
postranslational modifications, splicing isoforms of the same protein, specificity of tissue 
expressions, all together multiply and complicate input data. But the integration of genomic, 
transcriptomic and proteomic data with classical signalling activation information is 
probably indicated to meet the real complexity of a biological sample [29]. This kind of 
very ambitious work, increasing study in every fields and the development of new 
techniques will certainly implement our knowledge on CRC and will guide scientists 
towards new possibility for efficient clinical diagnosis and maybe screening of CRC. 
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